Dr Hyman presents data from the SUMMIT trial at a press conference at AACR 2017, in which patients with solid tumours displaying mutations in HER2 or HER3 were treated with neratinib, and their response assessed. He describes positive responses in HER2...
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2oqGHDI
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Publication date: Available online 2 November 2017 Source: Experimental Cell Research Author(s): Shanwu Wei, Chunxia Luo, Shanping Yu, Ji...
-
ACS Nano DOI: 10.1021/acsnano.6b08176 from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2k7Nvp8 via...
-
CFS, also known as ME, may be caused by the body switching from fully breaking down carbohydrates to using other energy sources, bringing o...
-
Commentary on: FørsundLHKiikRSkovdahlK. Constructing togetherness throughout the phases of dementia: a qualitative study exploring how spou...
-
You could soon get an even more immersive VR experience thanks to the Ambiotherm plug in, which exposes you to the elements of your virtual...
-
Abstract Objective A large proportion of paediatric patients with attention-deficit/hyperactivity disorder (ADHD) have associated sleep ...
-
Resume Rebuilders is an established provider of top-notch professional resume writing and editing services. Our certified resume writers pro...
-
Abstract A membrane filtration system was used to remove organic compounds, suspended solids, colour and turbidity from anaerobically trea...
-
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2oaY9u2 via IFTTT
-
Cancerous tumours are voracious. Once they have consumed all the oxygen and nutrients in the original tumour site, the cancer cells travel t...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου